Specify a stock or a cryptocurrency in the search bar to get a summary
Alumis Inc. Common Stock
ALMSAlumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California. Address: 280 East Grand Avenue, South San Francisco, CA, United States, 94080
Analytics
WallStreet Target Price
32.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALMS
Dividend Analytics ALMS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALMS
Stock Valuation ALMS
Financials ALMS
Results | 2019 | Dynamics |